OBI Pharma, Inc
OBI Pharma is a global clinical stage oncology company dedicated to developing innovative cancer therapies, including antibody-drug conjugates (ADCs) and active immunotherapies. With a focus on unmet medical needs, the company advances next-generation technologies and collaborates globally to bring first-in-class and best-in-class drugs to market, aiming to improve patient outcomes and quality of life.
Industries
Nr. of Employees
small (1-50)
OBI Pharma, Inc
6F., No.508, Sec. 7, Zhongxiao E. Rd., Nangang Dist., Taipei City, Taiwan
Patents
Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
US-12053514-B2
View Details
Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
US-12053514-B2
View DetailsProducts
Clinical-stage ADC therapeutic candidates (multiple targets)
A portfolio of clinical and preclinical ADC candidates targeting tumor antigens (including TROP2, Nectin4, HER2 and dual-antigen formats) developed using site-specific conjugation and linker technologies.
Enzyme-activated prodrug candidates
Prodrug molecules designed to be activated by tumor-associated enzymes to selectively release cytotoxic agents within cancer cells.
Clinical-stage ADC therapeutic candidates (multiple targets)
A portfolio of clinical and preclinical ADC candidates targeting tumor antigens (including TROP2, Nectin4, HER2 and dual-antigen formats) developed using site-specific conjugation and linker technologies.
Enzyme-activated prodrug candidates
Prodrug molecules designed to be activated by tumor-associated enzymes to selectively release cytotoxic agents within cancer cells.
Services
Licensing and transferring enabling ADC technologies and know-how to partners, including master services and marketing agreements to expand regional adoption of conjugation and glycan production capabilities.
Execution of multi-phase clinical programs and preparation of regulatory filings (IND/CTA) to advance oncology candidates through clinical development.
Out-licensing of therapeutic candidates and support for commercialization strategies including market partnerships and transfer of product rights to affiliates or partners.
Licensing and transferring enabling ADC technologies and know-how to partners, including master services and marketing agreements to expand regional adoption of conjugation and glycan production capabilities.
Execution of multi-phase clinical programs and preparation of regulatory filings (IND/CTA) to advance oncology candidates through clinical development.
Out-licensing of therapeutic candidates and support for commercialization strategies including market partnerships and transfer of product rights to affiliates or partners.
Expertise Areas
- Antibody-drug conjugate development
- Glycoscience and glycan engineering
- Linker and conjugation chemistry
- Bispecific and multi‑payload ADC engineering
Key Technologies
- Glycan-based site-specific conjugation
- Cysteine-selective conjugation chemistry
- Hydrophilic linker chemistry
- Endoglycosidase-mediated transglycosylation
News & Updates
OBI Pharma (4174.TWO) convened its 2025 Annual General Shareholders’ Meeting and announced a strategic focus on ADCs, out-licensing products and platform technologies to drive global collaboration.
OBI Pharma participated in the 4th World ADC Asia Summit with presentations and posters showcasing its latest research achievements in ADC technology.
OBI Pharma entered into a Master Services Agreement with TegMine Therapeutics to collaborate on ADC technologies using GlycOBI® and TegMiner™.
OBI Pharma debuted its ThiOBI® platform and HYPrOBI™ linker technology at the AACR Annual Meeting, demonstrating advanced ADC development capabilities.
OBI Pharma was recognized for its promising immunotherapy pipeline, including TROP2 ADC research.
Research on OBI-992, a TROP2-targeted ADC, demonstrating resistance profiles and antitumor activity.
OBI Pharma (4174.TWO) convened its 2025 Annual General Shareholders’ Meeting and announced a strategic focus on ADCs, out-licensing products and platform technologies to drive global collaboration.
OBI Pharma participated in the 4th World ADC Asia Summit with presentations and posters showcasing its latest research achievements in ADC technology.
OBI Pharma entered into a Master Services Agreement with TegMine Therapeutics to collaborate on ADC technologies using GlycOBI® and TegMiner™.
OBI Pharma debuted its ThiOBI® platform and HYPrOBI™ linker technology at the AACR Annual Meeting, demonstrating advanced ADC development capabilities.
OBI Pharma was recognized for its promising immunotherapy pipeline, including TROP2 ADC research.
Research on OBI-992, a TROP2-targeted ADC, demonstrating resistance profiles and antitumor activity.